During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used
medical intervention in children with cerebral palsy. In this review we consider the gaps in …

The long‐term effects of botulinum toxin A (BoNT‐A) treatment in children with cerebral
palsy (CP) are still elusive. We studied a prospective clinical cohort of 94 children with …

Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with
cerebral palsy (CP), especially in the hands of experienced injectors and for the majority of …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …

Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

Wallen MA, O'Flaherty SJ, Waugh M-CA. Functional outcomes of intramuscular botulinum
toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med …

Despite several trials showing reductions in tone and improvements in gait, the relation
between botulinum toxin A (BTX-A) dose and response has rarely been investigated. A …

The intramuscular application of botulinum toxin type A (BoNT/A) has emerged to be an
established treatment option to reduce muscular hyperactivity due to spasticity in children …

The efficacy of local injection of botulinum toxin A in selected skeletal muscles to relieve
muscle hypertonia and muscle contracture, and increase range of motion in children with …

BACKGROUND Cerebral palsy is the commonest cause of severe physical disability in
childhood. For many years treatment has centred on the use of physiotherapy and orthotics …